Dynavax shares soar as FDA clears hep B trial

Over at FierceVaccines this morning, we take a look at several key biotech developments. Dynavax Technologies' shares soared 75 percent after the FDA lifted its clinical hold on the developer's late-stage program for the Heplisav hepatitis B vaccine. In a move that will give a big boost to marketing efforts for HPV vaccines, an FDA expert panel voted to back GlaxoSmithKline's long delayed application to market its HPV vaccine Cervarix to women and soon after supported Merck's application to extend the use of Gardasil to males. And Vical is touting promising data on the immune response delivered by its experimental swine flu vaccine in an animal study. Vical plans to move the vaccine into a human trial as soon as possible. Report

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.